Frontiers in Immunology · Nov 10, 2026
Metabolic Fitness of CAR T-cell Therapy: An Aging Approach
By Migue Angel Sarabia-Sánchez, Eduardo Alvarado Ortiz, Jared Becerril-Rico et al.
Chimeric antigen receptor (CAR) T-cell therapy represents the cutting edge of modern cancer immunotherapy. However, aging impairs T-cell function and limits the applicability of CAR T-cell therapy in clinical oncology as the vast majority of patients with cancer are older than 60 years. To address this challenge, we must turn to a field that, paradoxically, is well recognized in clinical practice but has received relatively little attention in the context of this therapy: the CAR T-cell fitness. This review discusses how the relationship between metabolism and CAR T-cells can be leveraged to overcome current limitations. We examine this topic from two main perspectives: the impact of aging on CAR T-cell function; and the restructuring of CAR T-cell therapy to incorporate metabolic cues that enhance the CAR T-cell responses, including CAR design, manufacturing and clinical application. We describe how aging influences CAR T-cell biology through immunosenescence, mitochondrial dysfunction, and local and systemic inflammation. This evidence also supports the consideration of age as an important factor in clinical decision-making when selecting patients for CAR T-cell therapy, although additional meta-analyses will be needed to strengthen this concept. Finally, we highlight how redirecting basic research toward aging models will facilitate further advances and broaden the outlook of CAR T-cell therapy.